Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

ABSTRACT:

Objectives

Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tumors. This specific active immunotherapy is able to reduce platelet VEGF levels; however it is unknown whether this effect leads to a decrease in VEGF below the levels that can be observed in healthy individuals. The objective of the present study is to investigate platelet VEGF levels in cancer patients vaccinated with CIGB-247, and then compare these values with those obtained in healthy individuals. To achieve this, platelet VEGF levels of 62 cancer patients and 93 healthy individuals were comp

SUBMITTER: Sanchez Ramirez J 

PROVIDER: S-EPMC6558718 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature